Infliximab

Gastroenterology

Gastroenterology · Anti-TNF monoclonal antibody

Infliximab

Dose

5 mg/kg IV at 0, 2 and 6 weeks then 8-weekly; escalate to 10 mg/kg or 4-weekly if loss of response.

Use

Moderate-severe Crohn's/UC, acute severe UC rescue, RA, ankylosing spondylitis.

Monitoring

Screen TB (IGRA + CXR), HBV/HCV/HIV before start; drug levels and antibodies if failing.

Side effects

  • Infusion reaction
  • Reactivation TB / hepatitis B
  • Serious infection
  • Drug-induced lupus

Related in WardRound

Always confirm dose against your local formulary / BNF before prescribing.

WardRound

WardRound

Clinical Decisions in Seconds